Retina Associates is a Tucson, Arizona, retina practice that follows advancing research on dry age-related macular degeneration (AMD) and geographic atrophy. Retina Associates follows these developments as part of its ongoing interest in retinal disease research and the clinical questions patients often discuss with retina specialists.

The practice recognizes Izervay as an FDA-approved intravitreal therapy for geographic atrophy, the advanced form of dry AMD. Clinical evidence from the GATHER1 and GATHER2 trials examined whether avacincaptad pegol could slow geographic atrophy progression. This research provides a reference point for discussions about the changing retinal treatment landscape.

The firm also tracks trials such as Luna and Parasol, along with investigational gene therapy approaches for retinal conditions. Gene therapy studies for dry AMD are exploring subretinal delivery while continuing to evaluate safety and clinical effects. The practice’s interest in research reflects attention to developments beyond established care options.

Dr. Cameron Javid also serves as a clinical associate professor of ophthalmology at the University of Arizona College of Medicine. His Tucson practice maintains professional connections with organizations including the American Society of Retina Specialists, the American Academy of Ophthalmology, and the Arizona Ophthalmological Society.